Recently, with the introduction of high-throughput technologies, numerous multigene tests such as urokinase plasminogen activator (uPA)-PAI-1, Oncotype DX, MammaPrint, EndoPredict, Breast Cancer Index (BCI) and Prosigna (PAM50), may be performed in specific subgroups of BC patients to predict outcome and aid adjunct therapy decision-making [2]. This evidence concerns the gene PLAU and breast cancer.